Capital Research Global Investors Has $88.06 Million Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Capital Research Global Investors increased its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 29.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,911,525 shares of the company's stock after buying an additional 433,484 shares during the quarter. Capital Research Global Investors owned 6.83% of Establishment Labs worth $88,064,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. acquired a new stake in shares of Establishment Labs during the fourth quarter worth about $12,898,000. William Blair Investment Management LLC raised its holdings in Establishment Labs by 44.1% during the 4th quarter. William Blair Investment Management LLC now owns 812,825 shares of the company's stock worth $37,447,000 after buying an additional 248,888 shares during the period. Portolan Capital Management LLC boosted its holdings in shares of Establishment Labs by 243.1% in the fourth quarter. Portolan Capital Management LLC now owns 193,991 shares of the company's stock valued at $8,937,000 after buying an additional 137,458 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Establishment Labs during the fourth quarter worth $5,494,000. Finally, Royce & Associates LP acquired a new stake in shares of Establishment Labs during the fourth quarter worth $4,862,000. 72.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ESTA has been the subject of a number of research reports. Needham & Company LLC assumed coverage on Establishment Labs in a report on Monday, April 14th. They set a "hold" rating for the company. Stephens reiterated an "overweight" rating and set a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Establishment Labs presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.40.

Establishment Labs Stock Up 3.5 %

Shares of NASDAQ:ESTA traded up $1.00 during midday trading on Wednesday, reaching $29.78. The company had a trading volume of 755,393 shares, compared to its average volume of 456,459. The business's 50 day moving average price is $36.32 and its 200 day moving average price is $39.42. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $60.12. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The stock has a market cap of $859.03 million, a PE ratio of -11.54 and a beta of 0.77.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Research analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.